Replimune Group Inc

NASDAQ REPL

Download Data

Replimune Group Inc Operating Income to Total Debt for the quarter ending March 31, 2024: -1.21

Replimune Group Inc Operating Income to Total Debt is -1.21 for the quarter ending March 31, 2024, a 26.21% change year over year. The operating income to total debt ratio measures the ability of a company's operating income to cover its total debt obligations. It is calculated by dividing the operating income by the total debt. This ratio provides insights into the company's ability to generate income from its operations to service its debt. A higher ratio indicates a stronger capacity to generate operating income relative to the level of debt, suggesting potential financial strength and debt servicing capability.
  • Replimune Group Inc Operating Income to Total Debt for the quarter ending March 31, 2023 was -1.64.
  • Replimune Group Inc Operating Income to Total Debt for the quarter ending March 31, 2020 was -1.25.
NASDAQ: REPL

Replimune Group Inc

CEO Mr. Philip Astley-Sparke FSA
IPO Date July 20, 2018
Location United States
Headquarters 500 Unicorn Park Drive, Woburn, MA, United States, 01801
Employees 331
Sector Healthcare
Industry Biotechnology
Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Similar companies

UTHR

United Therapeutics Corporation

NA

NA

KURA

Kura Oncology Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

PRTC

PureTech Health PLC

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email